Department of Surgical Sciences, Città Della Salute e Della Scienza, University of Torino, Turin, Italy.
Unit of Emergency Surgery, Careggi University Hospital, Florence, Italy.
Tech Coloproctol. 2023 Jun;27(6):481-490. doi: 10.1007/s10151-023-02800-7. Epub 2023 Apr 25.
To evaluate the potential benefits associated with the short-term (6 months) treatment with transanal irrigation (TAI) in patients suffering from functional constipation (FC), functional fecal incontinence (FI), and low anterior resection syndrome (LARS).
A multicenter observational study (12 centers; 369 patients) was conducted to assess the following primary and secondary objectives: to evaluate the level of satisfaction regarding bowel control and quality of life (QoL); to evaluate bowel symptoms severity and dropout frequency and reason. To this aim, validated questionnaires were provided to the patients at baseline (T0) and after 6 months of TAI treatment (T6) performed with the medical device Peristeen Plus (Coloplast A/S, Denmark). Statistical analyses were conducted to compare the outcomes obtained at T0 and T6.
A 6-month treatment with TAI enabled a statistically significant (p < 0.05) improvement of QoL scores, satisfaction scores regarding bowel control, and severity indexes of disorder-related symptoms in patients suffering from FC, FI, and LARS. Globally, 8.0% of patients discontinued the treatment after 6 months as a result of occurrence of symptoms (2.4%) or other justifications (3.8%) such as personal reasons. None of the dropouts were due to treatment inefficacy.
Results of the present study suggest that short-term TAI treatment is beneficial for patients suffering from functional bowel disorders and LARS. Future analysis of prospective data will focus on the clinical outcomes associated with the long-term use (up to 24 months) of TAI when dealing with these types of medical conditions.
评估经肛门灌洗(TAI)短期(6 个月)治疗对功能性便秘(FC)、功能性粪便失禁(FI)和低位前切除综合征(LARS)患者的潜在益处。
进行了一项多中心观察性研究(12 个中心;369 例患者),以评估以下主要和次要目标:评估对肠道控制和生活质量(QoL)的满意度;评估肠道症状严重程度以及退出频率和原因。为此,在基线(T0)和 TAI 治疗 6 个月后(T6)使用医疗设备 Peristeen Plus(丹麦科洛普公司)向患者提供了经过验证的问卷。进行了统计分析,以比较 T0 和 T6 获得的结果。
TAI 治疗 6 个月可显著(p<0.05)改善 FC、FI 和 LARS 患者的 QoL 评分、对肠道控制的满意度以及与疾病相关症状严重程度指数。总体而言,8.0%的患者因出现症状(2.4%)或其他原因(3.8%,如个人原因)而在 6 个月后停止治疗。没有因治疗无效而退出的患者。
本研究结果表明,短期 TAI 治疗对功能性肠病和 LARS 患者有益。未来对前瞻性数据的分析将侧重于 TAI 长期(长达 24 个月)使用时与这些疾病类型相关的临床结果。